Sökning: id:"swepub:oai:lup.lub.lu.se:ed877298-9bcf-44ae-961a-e40f9c499cd2" >
Predictive and prog...
-
Taipale, KUniversity of Helsinki
(författare)
Predictive and prognostic clinical variables in cancer patients treated with adenoviral oncolytic immunotherapy
- Artikel/kapitelEngelska2016
Förlag, utgivningsår, omfång ...
Nummerbeteckningar
-
LIBRIS-ID:oai:lup.lub.lu.se:ed877298-9bcf-44ae-961a-e40f9c499cd2
-
https://lup.lub.lu.se/record/ed877298-9bcf-44ae-961a-e40f9c499cd2URI
-
https://doi.org/10.1038/mt.2016.67DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:art swepub-publicationtype
-
Ämneskategori:ref swepub-contenttype
Anmärkningar
-
The development of oncolytic viruses has recently made great progress towards being available to cancer patients. With the breakthrough into clinics, it is crucial to analyze the existing clinical experience and use it as a basis for treatment improvements. Here we report clinical data from 290 patients treated with oncolytic adenovirus. Using clinical variables and treatment characteristics, we constructed statistical models with regard to treatment response and overall survival. Additionally, we investigated effects of neutralizing antibodies, tumor burden and peripheral blood leucocyte counts on these outcomes. We found the absence of liver metastases to correlate with an improved rate of disease control (p=0.021). In multivariate evaluation, patients treated with viruses coding for immunostimulatory granulocyte macrophage colony-stimulating factor were linked to better prognosis (HR 0.378, p<0.001), as well as women with any cancer type (HR 0.694, p=0.017). In multivariate analysis for imaging response, patients treated via intraperitoneal injection were more likely to achieve disease control (OR 3.246, p=0.027). Patients with low neutrophil-to-lymphocyte ratio before treatment, had significantly longer overall survival (p<0.001). These findings could explain some of the variation seen in treatment outcomes after virotherapy. Furthermore, the results offer hypotheses for treatment optimization and patient selection in oncolytic adenovirus immunotherapy.Molecular Therapy (2016); doi:10.1038/mt.2016.67.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Liikanen, IUniversity of Helsinki
(författare)
-
Koski, AUniversity of Helsinki
(författare)
-
Heiskanen, RTargovax ASA
(författare)
-
Kanerva, AUniversity of Helsinki
(författare)
-
Hemminki, OUniversity of Helsinki
(författare)
-
Oksanen, MUniversity of Helsinki
(författare)
-
Grönberg-Vähä-Koskela, SUniversity of Helsinki
(författare)
-
Hemminki, KLund University,Lunds universitet,Allmänmedicin och klinisk epidemiologi,Forskargrupper vid Lunds universitet,Family Medicine and Clinical Epidemiology,Lund University Research Groups,German Cancer Research Centre(Swepub:lu)med-khk
(författare)
-
Joensuu, TDocrates Cancer Center
(författare)
-
Hemminki, AUniversity of Helsinki
(författare)
-
University of HelsinkiTargovax ASA
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Molecular Therapy: Elsevier BV24:7, s. 1323-13321525-00241525-0016
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Taipale, K
-
Liikanen, I
-
Koski, A
-
Heiskanen, R
-
Kanerva, A
-
Hemminki, O
-
visa fler...
-
Oksanen, M
-
Grönberg-Vähä-Ko ...
-
Hemminki, K
-
Joensuu, T
-
Hemminki, A
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Molecular Therap ...
- Av lärosätet
-
Lunds universitet